EIGR

Lonafarnib (Ritonavir)

Hepatitis Delta Virus

Phase 3

Exp Date

2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Lonafarnib (Ritonavir) for Hepatitis Delta Virus

  • ClinicalTrials.gov (NCT03719313) Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a (D-LIVR)


WHAT IS THE CATALYST EVENT?

  • Phase 3 D-LIVR study full enrollment expected in 2021


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 2021


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • After HDV enters a target cell hepatocyte, the genome is translocated to the nucleus where genome replication occurs without the need of any gene products from HBV. An important interaction between HDV and HBV proteins has been shown to depend on the presence of the last 4 amino acids of the large delta antigen, comprising a CXXX box motif, where C represents cysteine and X denotes any other amino acid. This amino acid sequence is required for the protein to be post-translationally modified by farnesyltransferase (FT), an enzyme which covalently attaches a 15-carbon prenyl-lipid farnesyl moiety to the cysteine of the CXXX box. Prenylation of the large delta antigen renders it more lipophilic, promotes its association with HBsAg, and is essential for initiating the HDV particle formation process.

Updated by JM 

#EIGR, EIGER, HDV, Hepatitis Delta Virus Infection, Lonafarnib/Ritonavir for HDV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

EIGR - Eiger BioPharmaceutical...

Summary: Zokinvy increases survival by 2.5 years in children and young adults with Progeria Rare Pediatric Disease Priority Review Voucher issued to Eiger from FDA Eiger to host an investor call, Nove...

EIGR - Announces Results of In...

#EIGR "announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.  The primary endpoint was duration of viral shed...

EIGR - Eiger Announces Peginte...

Summary: Week 48 (24 Weeks Post-Treatment) Results Presented 23% of Patients BLOQ or Undetectable HDV RNA at Week 48 55% of Patients Improved in Histology Activity Index (HAI) at Week 48 #EIGR "today...

EIGR - Eiger BioPharmaceutica...

Summary: Lambda significantly accelerated viral decline Viral clearance highly correlated with baseline viral loads- All Lambda-treated patients were below the infectivity threshold by Day 7 #EIGR "...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon